Haahr, Hanne

Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady‐state conditions in type 1 diabetes

Heise, T., Hermanski, L., Nosek, L., Feldman, A., Rasmussen, S., & Haahr, H. (2012) · Diabetes, Obesity and Metabolism

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 397

Ultra‐long‐acting insulin degludec has a flat and stable glucose‐lowering effect in type 2 diabetes

Heise, T., Nosek, L., Bøttcher, S. G., Hastrup, H., & Haahr, H. (2012) · Diabetes, Obesity and Metabolism

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 331

Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart

Vague, P., Selam, J.-L., Skeie, S., De Leeuw, I., Elte, J. W. F., Haahr, H., Kristensen, A., & Draeger, E. (2003) · Diabetes Care

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 294

A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance

Haahr, H., & Heise, T. (2014) · Clinical Pharmacokinetics

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 226

A pooled analysis of clinical pharmacology trials investigating the pharmacokinetic and pharmacodynamic characteristics of fast-acting insulin aspart in adults with type 1 diabetes

Heise, T., Pieber, T. R., Danne, T., Erichsen, L., & Haahr, H. (2017) · Clinical Pharmacokinetics

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 182

A Comparison of the Steady-State Pharmacokinetic and Pharmacodynamic Profiles of 100 and 200 U/mL Formulations of Ultra-Long-Acting Insulin Degludec

Korsatko, S., Deller, S., Koehler, G., Mader, J. K., Neubauer, K., Adrian, C. L., Thomsen, H., Haahr, H., & Pieber, T. R. (2013) · Clinical Drug Investigation

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 89

Insulin Degludec: Pharmacokinetics in Patients with Renal Impairment

Kiss, I., Arold, G., Roepstorff, C., Bøttcher, S. G., Klim, S., & Haahr, H. (2014) · Clinical Pharmacokinetics

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 75

Insulin degludec's ultra-long pharmacokinetic properties observed in adults are retained in children and adolescents with type 1 diabetes: Insulin degludec in children/adolescents

Biester, T., Blaesig, S., Remus, K., Aschemeier, B., Kordonouri, O., Granhall, C., Søndergaard, F., Kristensen, N. R., Haahr, H., & Danne, T. (2014) · Pediatric Diabetes

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 53

Glucose-Lowering Effect of Insulin Degludec is Independent of Subcutaneous Injection Region

Nosek, L., Coester, H.-V., Roepstorff, C., Thomsen, H. F., Kristensen, N. R., Haahr, H., & Heise, T. (2014) · Clinical Drug Investigation

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 42

Insulin Degludec: Pharmacokinetic Properties in Subjects with Hepatic Impairment

Kupčová, V., Arold, G., Roepstorff, C., Højbjerre, M., Klim, S., & Haahr, H. (2014) · Clinical Drug Investigation

Diabetes Management and ResearchGrowth Hormone and Insulin-like Growth Factors

Cited by 40

Ultra-Long Pharmacokinetic Properties of Insulin Degludec are Comparable in Elderly Subjects and Younger Adults with Type 1 Diabetes Mellitus

Korsatko, S., Deller, S., Mader, J. K., Glettler, K., Koehler, G., Treiber, G., Urschitz, M., Wolf, M., Hastrup, H., Søndergaard, F., et al. (2014) · Drugs & Aging

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 37

Insulin degludec is not associated with a delayed or diminished response to hypoglycaemia compared with insulin glargine in type 1 diabetes: a double-blind randomised crossover study

Koehler, G., Heller, S., Korsatko, S., Roepstorff, C., Rasmussen, S., Haahr, H., & Pieber, T. R. (2014) · Diabetologia

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 29

Pharmacokinetic and Pharmacodynamic Responses of Insulin Degludec in African American, White, and Hispanic/Latino Patients With Type 2 Diabetes Mellitus

Hompesch, M., Morrow, L., Watkins, E., Roepstorff, C., Thomsen, H. F., & Haahr, H. (2014) · Clinical Therapeutics

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 20